Tesaro’s Niraparib Takes PARP Inhibitor Lead In Ovarian Cancer

27 Aug 2013

• By Shirley Haley

Tesaro Inc. announced the launch of a Phase III trial for its PARP inhibitor niraparib in ovarian cancer, while registrational data from three global Phase III studies for anti-emetic rolapitant are due by the end of 2013.

Tesaro’s Niraparib Takes PARP Inhibitor Lead In Ovarian Cancer

More from Clinical Trials

More from R&D